ViGenCell Inc.
ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic unive… Read more
ViGenCell Inc. (308080) - Total Liabilities
Latest total liabilities as of September 2025: ₩9.38 Billion KRW
Based on the latest financial reports, ViGenCell Inc. (308080) has total liabilities worth ₩9.38 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ViGenCell Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how ViGenCell Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ViGenCell Inc. Competitors by Total Liabilities
The table below lists competitors of ViGenCell Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cheil Electric Wiring Devices Co. Ltd.
KQ:199820
|
Korea | ₩74.03 Billion |
|
O3 Mining Inc
OTCQX:OIIIF
|
USA | $31.97 Million |
|
Creditwest Faktoring AS
IS:CRDFA
|
Turkey | TL1.37 Billion |
|
Hazer Group Limited
PINK:HZRGF
|
USA | $3.40 Million |
|
Pyrum Innovations AG
OL:PYRUM
|
Norway | Nkr42.95 Million |
|
Pulmonx Corp
NASDAQ:LUNG
|
USA | $75.17 Million |
|
Naked Wines plc
PINK:MJWNY
|
USA | $107.52 Million |
|
Shenwan Hongyuan (H.K.) Limited
F:WAY
|
Germany | €9.44 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down ViGenCell Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ViGenCell Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ViGenCell Inc. (2019–2024)
The table below shows the annual total liabilities of ViGenCell Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩9.32 Billion | -2.50% |
| 2023-12-31 | ₩9.56 Billion | -1.75% |
| 2022-12-31 | ₩9.73 Billion | -19.52% |
| 2021-12-31 | ₩12.09 Billion | -78.83% |
| 2020-12-31 | ₩57.12 Billion | +10.27% |
| 2019-12-31 | ₩51.80 Billion | -- |